MSF authors analyse R&D and regulatory approval of DR-TB drugs bedaquiline and delamanid, and impact on treatment outcomes and access.

The WHO recently released new rapid guidance recommending that children of all ages with drug-resistant tuberculosis (DR-TB) have access to all-oral treatment using the drugs bedaquiline and/or delamanid. However paediatric ...

Next week the Indian government is expected to decide whether it is willing to override patents on two critical tuberculosis (TB) drugs following a court petition filed at the Mumbai High Court by two survivors of TB and activists. MSF ...

TB survivors and activists raised their voices to demand better access to treatment at the world’s biggest tuberculosis conference.

Newer medicines for DR-TB are desperately needed, but barriers to access, including high prices, keep them out of reach for most people around the world.

MSF calls for new price of anti TB drug delamanid to be lowered and offered outside of South Africa

Bhakti’s Story: Strength to Survive Drug-Resistant TB

MSF welcomes new WHO treatment guidelines that recommend drug-resistant tuberculosis be treated with oral drugs only, including newer, more potent drugs with fewer side effects, such as bedaquiline.

We call on US pharma corporation Johnson & Johnson to cut key TB drug price in half